metricas
covid
Buscar en
Atención Primaria
Toda la web
Inicio Atención Primaria Calidad del tratamiento farmacológico en pacientes con hiperlipemia de 4 áreas...
Journal Information
Vol. 26. Issue 6.
Pages 368-373 (January 2000)
Share
Share
Download PDF
More article options
Vol. 26. Issue 6.
Pages 368-373 (January 2000)
Full text access
Calidad del tratamiento farmacológico en pacientes con hiperlipemia de 4 áreas de salud
Quality of pharmacological treatment of patients with hyperlipaemia from four health districts
Visits
2548
T. Sanz Cuesta, E. Escortell Mayor*, M.I. Fernández San Martín, C. López Bilbao, B. Medina Bustillo, C. Torres Bouza, Grupo VICAF*
Áreas 3, 8, 9 y 10. INSALUD. Madrid
This item has received
Article information
Objetivo

Estimar la adecuación del tratamiento hipolipemiante prescrito a pensionistas en consultas de atención primaria de 4 áreas de salud.

Diseño

Estudio descriptivo transversal de calidad del tratamiento farmacológico.

Emplazamiento

Cuatro áreas de salud de atención primaria. INSALUD. Madrid.

Sujetos

Un total de 1.125 pacientes adscritos a 49 médicos, elegidos aleatoriamente a partir de 3 estratos definidos por el valor del indicador de prescripción de hipolipemiantes. Cada médico rellenó un protocolo de variables por cada pensionista al que indicó un hipolipemiante durante un año.

Mediciones y resultados principales

Se elaboró un algoritmo automatizado para valorar la adecuación del tratamiento farmacológico de cada paciente, según criterios científicos teniendo en cuenta: niveles de colesterol, LDL, edad y existencia de factores de riesgo. La calidad de la prescripción se midió finalmente en 1.009 pacientes. La indicación del tratamiento se debió a prevención primaria en un 65% de los casos. El 32% de pacientes estaba correctamente tratado. Si no se exige la cumplimentación de LDL, el porcentaje de adecuación asciende al 77%. El porcentaje de tratamiento farmacológico adecuado fue superior cuando lo realizó el propio facultativo (frente a otro facultativo o al especialista; p = 0,001) y cuando el paciente pertenecía al propio cupo del médico prescriptor (p < 0,0001). La correcta indicación fue menor en pacientes mayores de 74 años (p < 0,0001).

Conclusiones

La calidad de la indicación de hipolipemiantes a pensionistas en consultas de atención primaria de 4 áreas de salud, en función de los criterios previamente definidos, es mejorable, siendo la LDL el factor que más influye en el proceso.

Palabras clave:
Atención primaria
Calidad
Hiperlipemia
Tratamiento farmacológico
Objective

To calculate how suitable the lipid-lowering treatment prescribed for pensioners in primary care clinics in four health areas is.

Design

Cross-sectional descriptive study of quality of pharmacological treatment.

Setting

Four primary care health districts, INSALUD, Madrid.

Participants

1125 patients registered with 49 doctors, chosen at random on the basis of three strata defined by the value of the lipid-lowering drug indicator of prescription. For a year, each doctor filled in a protocol of variables for each pensioner to whom he/she prescribed a lipid-lowering drug.

Measurements and main results

An automated algorithm was designed to evaluate the suitability of the drugs treatment for each patient, according to scientific criteria including: cholesterol levels, LDL, age, and risk factors. Quality of prescription was finally measured for 1009 patients. The indication of the treatment was due to primary prevention in 65% of cases. 32% of patients were correctly treated. If LDL compliance was not demanded, the suitability figure rose to 77%. Drug treatment was more suitable when the doctor him/herself administered it (as against another doctor or a specialist; p = 0.001) or when the patient was on the list of the prescribing doctor (p < 0.0001). Proper indication was lower in patients over 74 (p < 0.0001).

Conclusions

The quality of lipid-lowering drug prescription for pensioners in primary care clinics in four health districts, as a function of the criteria defined above, could be improved. LDL is the factor which most affects the procedure.

Full text is only aviable in PDF
Bibliografía
[1.]
Comité de Expertos para la Detección, Evaluación y Tratamiento de la Hipercolesterolemia en Adultos.
Resumen del Segundo Informe del National Cholesterol Education Program (NCEP) por el Comité de Expertos para la Detección, Evaluación y Tratamiento de la Hipercolesterolemia en Adultos (Adult Treatment Panel II).
JAMA (ed. esp.), 2 (1993), pp. 670-681
[2.]
Scandinavian Simvastatin Survival Study Group.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[3.]
Manejo de las dislipemias en atención primaria.
[4.]
F. Villar, A. Maiques, C. Brotons, J. Torcal, A. Lorenzo, J. Canals, et al.
Recomendaciones preventivas cardiovasculares: aplicaciones prácticas del riesgo cardiovascular.
Aten Primaria, 24 (1999), pp. 66-75
[5.]
Management of hyperlipidaemia.
Drug Ther Bull, 34 (1996), pp. 89-93
[6.]
F.M. Sacks, M.A. Pfeiffer, L.A. Moye, J.L. Rouleau, J.A. Ruthwerford, J.G. Cole, et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators.
N Engl J Med, 335 (1996), pp. 1001-1009
[7.]
D. Wood, G. De Backer, O. Faergeman, I. Graham, G. Mancia, K. Pyörälä.
Task Force Report. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other societies on Coronary Prevention.
Eur Heart J, 19 (1998), pp. 1434-1503
[8.]
J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. Macfarlane, et al.
West of Scotland Coronary Prevention Study.
N Engl J Med, 333 (1995), pp. 1301-1307
[9.]
The WHO MONICA Project.
A world wide monitoring system for cardiovascular diseases.
pp. 43-44
[10.]
H.M. Krumholz, T.E. Seeman, S.S. Merrill, C.F. Mendes, V. Vacarino, D.I. Silverman, et al.
Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years.
JAMA, 272 (1994), pp. 1335-1340
[11.]
S.B. Hulley, T.B. Newman.
Cholesterol in elderly Is it important?.
JAMA, 272 (1994), pp. 1372-1374
[12.]
M. Corti, J.M. Guralnik, M.E. Salive, T. Harris, T.S. Field, R.B. Wallace, et al.
HDL cholesterol predicts coronary heart disease mortality in older persons.
JAMA, 274 (1995), pp. 539-544
[13.]
American College of Physicians.
Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults.
Ann Intern Med, 124 (1996), pp. 515-531
[14.]
N. Freemantle, R. Barbour, R. Johnson, M. Marchment.
The use of statins: a case of misleading priorities?.
BMJ, 315 (1997), pp. 826-828
[15.]
INSALUD.
Indicadores de la prestación farmacéutica en el Sistema Nacional de Salud. Vol. 16 Anual 1998 Ministerio de Sanidad y Consumo-INSALUD. Subdirección General de Atención Primaria.
[16.]
C. Baxter, R. Jones, L. Corr.
Time trend analysis and variations in prescribing lipid lowering drugs in general practice.
BMJ, 317 (1998), pp. 1134-1135
[17.]
C. Brotons, M. Server, X. Pintó, P. Roura, A. Martín-Zurro.
Impacto de los consensos para el control de la colesterolemia y la hipertensión en España.
Med Clin (Barc), 108 (1997), pp. 9-15
[18.]
E. Morales, S.A. Spinler, M.D. Wilson, M.M. Chin, E. Jozefiak.
American Society of Hospital Pharmacists. Criteria for use of hypolipidemic agents in adults.
Am J Hosp Pharm, 51 (1994), pp. 2837-2841
[19.]
J.P. Frolkis, S.J. Zyzanski, J.M. Schwartz, P.S. Suhan.
Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) Guidelines.
Circulation, 98 (1998), pp. 851-855
[20.]
G. Jackson.
Lipid-lowering therapy: guidelines, targets and the need for action.
IJCP, 52 (1998), pp. 211
[21.]
J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, et al.
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS.
JAMA, 279 (1998), pp. 1615-1622
[22.]
Prévention cardiovasculaire primaire et secondaire.
Rev Prescr, 19 (1999), pp. 281-288
[23.]
R. Lemaitre, C.D. Furberg, A.B. Newman, S.B. Hulley, D.J. Gordon, J.S. Gottdiener, et al.
Time trends in the use of cholesterollowering agents in older adults.
Arch Intern Med, 158 (1998), pp. 1761-1768
[24.]
N. Unwin, R. Thomson, A.M. O'Byrne, M. Laker, H. Armstrong.
Implications of applying widely accepted cholesterol screening and managemente guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors.
BMJ, 317 (1998), pp. 1125-1130
[25.]
R. Raine, A. Streetly, A.M. Davis.
Variation local policies and guidelines for cholesterol management: national survey.
BMJ, 313 (1996), pp. 1368-1369
Copyright © 2000. Elsevier España, S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos